Anti-biofilm Effect of β-Lapachone and Lapachol Oxime Against Isolates of Staphylococcus aureus

Fernandes, Antônio Wilton Cavalcante; Santos, Victória Laysna dos Anjos; Araújo, Cleônia Roberta Melo; Costa, Mateus Matiuzzi da

doi:10.1007/s00284-019-01818-1

Cited by 8 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanism behind the inhibition of biofilm formation and eradication of already formed biofilms needs to be investigated. Our results of antibacterial and antibiofilm activities of β-Lap corroborate well with the study of Fernandes AWC, et al, wherein the authors showed that β-Lap and Lapachol Oxime (semi-synthetic derivatives of Lapachol) exhibited antimicrobial and anti-biofilm potential against clinical isolates of S. aureus [ 26 ].…”

Section: Discussionsupporting

confidence: 91%

Antibacterial and Antibiofilm Activities of β-Lapachone by Modulating the Catalase Enzyme

et al. 2023

View full text Add to dashboard Cite

Background: Bacterial infections constantly have a large impact on public health, because of increased rates of resistance and reduced frequency of development of novel antibiotics. The utility of conventional antibiotics for treating bacterial infections has become increasingly challenging. The aim of the study was to assess the antibacterial effect of β-Lapachone (β-Lap), a novel synthetic compound. Methods: The antibacterial activity of the β-Lap compound was examined against laboratory strains by agar well diffusion method and broth dilution assay. Growth kinetics in presence of β-Lap on Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa (ATCC 27853) were assessed by microplate alamarBlue assay. Crystal violet blue assay was used for biofilm inhibition and biofilm eradication. P. aeruginosa catalase (KatA) complexed with β-Lap was modeled using molecular docking approach. Results: β-Lap exhibited potent antimicrobial activity against laboratory strains of bacteria with MIC of 0.2 mM for S. saprophyticus and Staphylococcus aureus, and 0.04 mM for Staphylococcus epidermidis and Pseudomonas aeruginosa ATCC 27853. The inhibition of catalase enzyme was found to be the cause for its antibacterial activity. Bioinformatics analysis suggests that β-Lap can inhibit KatA activity by interacting with catalase proximal active site and heme binding site. The activity of some commercial antibiotics was enhanced in association with β-Lap. In addition, β-Lap inhibited the biofilm formation and eradicated the already formed and ultra-mature biofilms of aforesaid bacterial strains. Conclusion: These observations indicated that β-Lap could be a promising antibacterial agent for the treatment and prevention of infectious diseases.

show abstract

Section: Discussionsupporting

confidence: 91%

Antibacterial and Antibiofilm Activities of β-Lapachone by Modulating the Catalase Enzyme

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Our results of antibacterial and antibiofilm activities of β -Lap corroborates well with the study of Fernandes AWC, et. al., wherein the authors showed that β-Lapachone and Lapachol Oxime (semi-synthetic derivatives of Lapachol) exhibited antimicrobial and anti-biofilm potential against clinical isolates of S. aureus (19).…”

Section: Discussionmentioning

confidence: 99%

Antibacterial and Antibiofilm Activities of Β –Lapachone by Modulating the Catalase Enzyme

Mir¹,

Altuhami²,

Mondal³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Bacterial infections constantly have a large impact on public health, because of increased rates of resistance and reduced frequency of development of novel antibiotics. The utility of conventional antibiotics for treating bacterial infections has become increasingly challenging. The aim of the study was to assess the antibacterial effect of β -Lapachone, a novel synthetic compound. Methods: The antibacterial activity of the β -Lapachone compound was examined against laboratory strains by agar well diffusion method, minimal inhibitory concentration (MICs), and minimal bactericidal concentration (MBCs). Growth kinetics inhibition in presence of β -Lapachone on Staphylococcus aureus, Staphylococcus epidermidis and Pseudomonas aeruginosa (ATCC 27853) was assessed by MABA. Crystal violet blue assay was used for biofilm inhibition assays, biofilm eradication assay and for molecular modeling PyMOL was used. Results: β -Lapachone exhibited potent antimicrobial activity against laboratory strains of bacteria with MIC of 0.2 mM for S. saprophyticus and Staphylococcus aureus, and 0.04 mM for Staphylococcus epidermidis and Pseudomonas aeruginosa ATCC 27853. The inhibition of catalase enzyme was found to be the cause for its antibacterial activity. Molecular modeling predicted the binding of β -Lap at active site and heme binding site of catalase, KatA. The activity of some commercial antibiotics was enhanced in association with β -Lap. In addition, β -Lap inhibited the biofilm formation and eradicated the already formed and ultra-mature biofilms of aforesaid bacterial strains.

show abstract

“…Another study showed that caffeine, which is a xanthine alkaloid compound, significantly inhibited the formation of P. aeruginosa biofilms at sub-MIC concentrations by interfering with QS [249]. β-Lapachone and lapachol oxime are semisynthetic derivatives of lapachol that were originally isolated from species of the Bignoniaceae family and have also been proven to be effective in inhibiting biofilm formation [250]. In addition, Warburgia ugandensis Sprague subspecies ugandensis is a plant that is widely distributed in Eastern, Central, and Southern Africa.…”

Section: Agents For Degradation Of the Extracellular Matrix Of Biofilmsmentioning

confidence: 99%

Novel Approaches to Combat Medical Device-Associated BioFilms

Sun

Zhang

et al. 2021

Coatings

View full text Add to dashboard Cite

Biofilms are aggregates formed as a protective survival state by microorganisms to adapt to the environment and can be resistant to antimicrobial agents and host immune responses due to chemical or physical diffusion barriers, modified nutrient environments, suppression of the growth rate within biofilms, and the genetic adaptation of cells within biofilms. With the widespread use of medical devices, medical device-associated biofilms continue to pose a serious threat to human health, and these biofilms have become the most important source of nosocomial infections. However, traditional antimicrobial agents cannot completely eliminate medical device-associated biofilms. New strategies for the treatment of these biofilms and targeting biofilm infections are urgently required. Several novel approaches have been developed and identified as effective and promising treatments. In this review, we briefly summarize the challenges associated with the treatment of medical device-associated biofilm infections and highlight the latest promising approaches aimed at preventing or eradicating these biofilms.

show abstract

Anti-biofilm Effect of β-Lapachone and Lapachol Oxime Against Isolates of Staphylococcus aureus

Cited by 8 publications

References 20 publications

Antibacterial and Antibiofilm Activities of β-Lapachone by Modulating the Catalase Enzyme

Antibacterial and Antibiofilm Activities of β-Lapachone by Modulating the Catalase Enzyme

Antibacterial and Antibiofilm Activities of Β –Lapachone by Modulating the Catalase Enzyme

Novel Approaches to Combat Medical Device-Associated BioFilms

Contact Info

Product

Resources

About